Indicated for: chronic myeloid leukemia
Route of administration: oral
Substance: bosutinib (tyrosine kinase inhibitor)
ATC: L01EA04 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | BCR-ABL tyrosine kinase inhibitors)
This medicine may affect fertility.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
Avoid grapefruit and grapefruit juice.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
This medicine may increase the risk of heart rhythm disturbances.
Bosutinib is a medication used for the treatment of chronic myeloid leukemia (CML) in adult patients with BCR-ABL gene mutations. It is a tyrosine kinase inhibitor that blocks the abnormal activity of the BCR-ABL protein, which drives the uncontrolled growth of leukemic cells.
The medication is taken orally, usually once daily, as directed by a doctor. The dosage may be adjusted based on the patient's response and tolerance to treatment.
Common side effects include nausea, diarrhea, vomiting, fatigue, and elevated liver enzyme levels. In rare cases, more severe adverse effects such as liver toxicity or fluid retention may occur.
Bosutinib is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.